Jack Sanborn Returns to Chicago Bears on One-Year Deal
The Chicago Bears have re-signed linebacker Jack Sanborn, bringing back a fan favorite on a one-year contract. Sanborn returns to the team after spending the 2025 season with the Dallas Cowboys.
Sanborn’s Career Trajectory
Sanborn initially joined the Bears as an undrafted free agent in 2022, quickly becoming a key contributor to the linebacker corps. He started 19 games for the Bears from 2022-2024. Following the 2024 season, he signed with the Dallas Cowboys to reunite with former Bears head coach Matt Eberflus, who had grow the Cowboys’ defensive coordinator.
2025 Season with the Cowboys
During the 2025 season with Dallas, Sanborn appeared in six games, making five starts. He recorded 34 tackles, one tackle for loss, and one pass breakup. However, his season was cut short due to a concussion in Week 5 against the Jets and later a groin injury in Week 7 against the Commanders, which led to him being placed on injured reserve Dallas Cowboys.
Impact on the Bears Linebacker Room
Sanborn’s return provides depth to a Bears linebacker group currently dealing with injuries. T.J. Edwards is recovering from a leg injury, and Noah Sewell is rehabilitating a torn Achilles’ tendon. The Bears recently signed Devin Bush to fill the role previously held by Tremaine Edmunds, who was released as a cap casualty. Sanborn is likewise expected to contribute on special teams Chicago Sun-Times.
Fan Reaction and Background
Sanborn, who will turn 26 in July, attended Lake Zurich High School. He quickly became a fan favorite in Chicago after joining the team as an undrafted free agent. His return has been met with enthusiasm from Bears fans Sports Illustrated.
Career Statistics
Over four seasons, Sanborn has played in 52 games, including 24 starts, totaling 183 tackles, 15 tackles for loss, and 15 special teams tackles.
- EPA Hosts G20 Regulatory Efficiency Symposium in Houston
- BGH Ruling: Sole Shareholders of UK Limiteds with German Seats Face Unlimited Liability after Brexit
- Bears-Panthers was highest-scoring Week 1 game in NFL history (newsylist.com)
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)